Literature DB >> 12588012

Outcome of tuberculosis treatment in Hamburg: a survey, 1997-2001.

R Diel1, S Niemann.   

Abstract

SETTING: Federal State of Hamburg, Germany, 1997-2001.
OBJECTIVE: To determine risk factors affecting the treatment outcome for tuberculosis according to the WHO/IUATLD classification.
DESIGN: Prospective evaluation among patients with culture-confirmed pulmonary disease due to Mycobacterium tuberculosis during the period 1997-1999.
RESULTS: Five hundred and eighteen (467 new and 51 re-treatment) cases started a course of treatment (average duration 36.1 +/- 15.5 weeks), resulting in cure for 416 (80.3%) and treatment completed for three (0.6%) patients; 449 patients (86.7%) initially received a three-drug regimen. Treatment interruption occurred in 54 (10.4%), and failure in 12 (2.3%) cases; 32 (6.2%) patients died (irrespective of cause). Alcohol dependence appeared to be the strongest risk factor for persistence of disease, followed by homelessness and unemployment. The risk of treatment interruption was six times higher among alcoholics (OR = 6.0), five times higher among drug abusers (OR = 5.2) and three times higher among the homeless (OR = 3.0) than in other patients.
CONCLUSION: Although the current treatment management in Hamburg is considered to be effective, a further improvement in the proportion of patients who complete treatment can be achieved by increased public health surveillance of subpopulations with the above-mentioned risk factors.

Entities:  

Mesh:

Year:  2003        PMID: 12588012

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  24 in total

1.  Predictors of treatment failure among pulmonary tuberculosis patients in Mulago hospital, Uganda.

Authors:  E Namukwaya; F N Nakwagala; F Mulekya; H Mayanja-Kizza; R Mugerwa
Journal:  Afr Health Sci       Date:  2011-08       Impact factor: 0.927

2.  Investigating urban-rural disparities in tuberculosis treatment outcome in England and Wales.

Authors:  I Abubakar; J P Crofts; D Gelb; A Story; N Andrews; J M Watson
Journal:  Epidemiol Infect       Date:  2007-03-15       Impact factor: 2.451

3.  The cost structure of lung tuberculosis in Germany.

Authors:  Roland Diel; Bernhard Rappenhöner; Tom Schaberg
Journal:  Eur J Health Econ       Date:  2004-10

4.  Adequacy of anti-tuberculosis drug prescriptions in Viet Nam.

Authors:  N B Hoa; J M Lauritsen; H L Rieder
Journal:  Public Health Action       Date:  2012-03-21

5.  Time to unsuccessful tuberculosis treatment outcome, Cambodia, China, and Viet Nam.

Authors:  N B Hoa; C Sokun; C Wei; J M Lauritsen; H L Rieder
Journal:  Public Health Action       Date:  2012-03-21

6.  Tuberculosis treatment outcome monitoring in England, Wales and Northern Ireland for cases reported in 2001.

Authors:  Delphine Antoine; Clare E French; Jane Jones; John M Watson
Journal:  J Epidemiol Community Health       Date:  2007-04       Impact factor: 3.710

7.  Factors associated with excessively lengthy treatment of tuberculosis in the eastern Paris region of France in 2004.

Authors:  Nadia Valin; Gilles Hejblum; Isabelle Borget; Henri-Pierre Mallet; Fadi Antoun; Didier Che; Christos Chouaid
Journal:  BMC Public Health       Date:  2010-08-18       Impact factor: 3.295

8.  Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance.

Authors:  I Y Gelmanova; S Keshavjee; V T Golubchikova; V I Berezina; A K Strelis; G V Yanova; S Atwood; M Murray
Journal:  Bull World Health Organ       Date:  2007-09       Impact factor: 9.408

9.  Alcohol use and clinical manifestations of tuberculosis.

Authors:  Christina T Fiske; Carol D Hamilton; Jason E Stout
Journal:  J Infect       Date:  2008-10-09       Impact factor: 6.072

10.  Clinical presentation, demographics and outcome of tuberculosis (TB) in a low incidence area: a 4-year study in Geneva, Switzerland.

Authors:  Omar Kherad; François R Herrmann; Jean-Pierre Zellweger; Thierry Rochat; Jean-Paul Janssens
Journal:  BMC Infect Dis       Date:  2009-12-31       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.